Drug Detail:Burosumab (Burosumab [ bur-oh-sue-mab ])
Drug Class: Miscellaneous metabolic agents
Drug Detail:Burosumab (Burosumab [ bur-oh-sue-mab ])
Drug Class: Miscellaneous metabolic agents
No information is available on the clinical use of burosumab alfa during breastfeeding. Because burosumab alfa is a large protein molecule with a molecular weight of about 170,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[1]
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Relevant published information was not found as of the revision date.
Relevant published information was not found as of the revision date.
Burosumab
1610833-03-8
Breast Feeding
Lactation
Milk, Human
Antibodies, Monoclonal
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.